Dr. Massimo Radaelli's main focus is to further expand Jaguar's commercial footprint outside the United States.
Dr. Radaelli was instrumental in facilitating Crofelemer's recent license-out agreement with GEN in Turkey and eight neighboring countries, which involved a $2 million investment at a premium price in Jaguar stock.
SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health Co., Ltd. (NASDAQ:JAGX) (“Jaguar”) today announced that Dr. Massimo Radaelli has been appointed President of Jaguar International. Dr. Radaelli is a European pharmaceutical industry leader and entrepreneur with more than 35 years of experience in the biopharmaceutical field and in innovating treatments specifically for rare diseases. He is a member of Therapeutics' Board of Directors. He briefly served as Interim Executive Director of Napo Therapeutics in 2021, focusing on expanding access to Crofermar in Europe.
“We are excited to have an experienced pharmaceutical leader of Massimo expand his role in the Jaguar family of companies as president of Jaguar International,” said Lisa Conte, president and CEO of Jaguar. “There is,” he said. “Additionally, the Napo Therapeutics Board of Directors is interested in Massimo entering and continuing in a leadership position at Napo Therapeutics, and this additional role for Massimo will be formalized in the future. It's a schedule.”
“As announced, last month we signed an agreement with Turkish specialty pharmaceutical company GEN that will allow us to commercialize the FDA-approved prescription drug crofelemer in Turkey and eight neighboring countries. It includes a $2 million investment in 75% of Jaguar's shares, “at a premium to the market,'' Conte said. “Massimo has been instrumental in making this agreement a reality. We are grateful for his vast pharmacology, clinical, business development and international commercialization experience and expertise as we continue to refine Jaguar's international business strategy. I am confident that the knowledge will prove invaluable.”
Dr. Radaelli's primary focus will be to further expand Jaguar's commercial footprint outside of the United States and improve the treatment of neglected symptoms across multiple complex disease states, including cancer, short bowel syndrome (SBS), and microvilli. and increasing access to supportive care and prescription medications for management. Inclusion Disease (MVID) – For people in need around the world.
“I came here for the same reason I think most people joined Jaguar Health: that we have an unparalleled ability to impact critical unmet health care needs. I believe that,” Dr. Radaelli said. “My job is to help ensure Jaguar's growth in therapeutic areas such as orphan medicines, rare diseases and supportive care, and to help Jaguar grow internationally through partnerships and direct presence in key key markets. It's about expanding our footprint. A lot of companies want to change treatment.”
Click to view a video clip of Dr. Radaelli speaking during Jaguar's April 1, 2024 investor webcast about why he decided to expand his role with the company. here.
In April 2023, Dr. Radaelli was recognized for his “services” and was appointed Commander of the Special Merit of the Republic of Italy, the highest honor bestowed on a civilian by the President of the Republic of Italy and the Prime Minister of Italy. in science and the biopharmaceutical industry, with a particular focus on rare and neglected diseases. ”
Dr. Radaelli founded Noventia Pharma in 2009 and serves as Chairman, President, and Chief Executive Officer. He also founded Pint Pharma Group and Ferrer Italia and was a co-founder of the Italian subsidiary of the Dupont-Merck joint venture. He served as President and Chief Executive Officer of Dompé International SA., an international pharmaceutical company of the Dompé Group. He joined Dompe in 1996 as Corporate Business Development Director and was responsible for the launch of Dompe's global strategy in his Swiss subsidiary and for strategic planning, licensing, partnerships, and new product opportunities in Europe. Did. Dr. Radaelli has held various executive positions including sales and marketing at Dupont-Merck Pharmaceutical Company, Hoffman-La Roche Ltd., and Menarini Group. He serves as executive chairman of his Bioakos Pharma. He has served on the boards of Dompe Farmaceutici SpA, Dompe SpA and Philogen SpA, which are privately held Italian biopharmaceutical companies. Dr. Radaelli served as a board member and vice chair of IDRI, a nonprofit organization focused on neglected diseases. From October 2008 until July 2016 he served as an independent director of Ariad Pharmaceuticals, and from January 2014 until May 2016 he served as a director of NovaBay Pharmaceuticals. Dr. Radaelli is a founder and served on the boards of Pint Pharma and Cytovia Therapeutics. Prior to joining Jaguar Health, Dr. Radaelli served as Vice President of International for Immunogen, now part of Abbvie. Dr. Radaelli received a degree in pharmacy from the university and his Ph.D. He holds a PhD in Clinical Pharmacology from the University of Milan and a Master of Business Administration from Bocconi University, Milan.
About the Jaguar Health Group of Companies
Jaguar Health, Inc. (Jaguar) is launching a novel, sustainably derived from plants from tropical rainforest regions for people and animals suffering from gastrointestinal disorders, particularly those associated with an overactive gut, including conditions such as chronic debilitating diarrhea. is a commercial stage pharmaceutical company focused on developing proprietary prescription medicines. , urgency, bowel incontinence. Napo Pharmaceuticals, a Jaguar family company, is focused on developing and commercializing prescription human medicines for essential supportive care and management of neglected gastrointestinal conditions across multiple complex disease states. Napo Pharmaceuticals' crofelemer drug candidate is in a pivotal Phase 3 clinical trial for the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adult cancer patients receiving targeted therapy. It is the subject of an OnTarget trial. Napo Therapeutics, a Jaguar family company, is an Italian entity founded by Jaguar in his 2021 year in Milan, Italy, with a particular focus on expanding access to crofelemer in Europe for orphans and/or rare diseases. Masu. Jaguar Animal Health is the brand name of Jaguar. Magdalena Biosciences, a joint venture between Jaguar and Filament Health Corporation born out of Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel plant-based prescription medicines for mental health indications. I am.
See below for more information.
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com.
For more information about Napo Therapeutics, please visit napotherapeutics.com.
Magdalena Biosciences, visit magdalenabiosciences.com
Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Forward-looking statements
Certain statements in this press release constitute “forward-looking statements.” These include a statement regarding the expectation that Dr. Radaelli's pharmacological, clinical, business development and international commercialization experience and expertise will prove invaluable as Jaguar Health continues to refine its international business strategy; It contains. In some cases, words such as “may”, “will”, “should”, “expect”, “plan”, “aim”, “anticipate”, “could”, “intend”, etc. Forward-looking statements may be identified by terminology such as “will''. “Aim,'' “plan,'' “contemplate,'' “believe,'' “estimate,'' “anticipate,'' “may,'' “continue,'' or the negative of these terms. , or other similar expressions. The forward-looking statements contained in this release are predictions only. Jaguar has based, in large part, these forward-looking statements on its current expectations and predictions about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which is beyond Jaguar's control. Except as required by applicable law, Jaguar will not publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances or otherwise. There are no plans to do so.
contact:
hello@jaguar.health
Jaguar-JAGX
sauce: Jaguar Health Co., Ltd.
View the original press release at accesswire.com